Loading...

Major Indexes

Operating Data

Cleveland BioLabs Inc.

Cleveland BioLabs Inc. (CBLI)

$2.17
-0.08 (-3.56%)

Operating Data

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 8.493.702.713.521.951.140.920.680.500.370.27
Revenue (%)
EBITDA -22.61-13.58-10.52-6.29-5.58-4.78-2.54-2.12-1.56-1.15-0.84
EBITDA (%)
EBIT -23.08-14.42-10.79-6.36-5.60-4.80-2.55-2.16-1.59-1.17-0.86
EBIT (%)
Depreciation 0.470.840.280.060.020.020.010.040.030.020.02
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)